After years of being the world's best-selling drug, Humira faces competition from copycat versions known as biosimilars. One called Yusimry costs a $1,000 or less.

U.S. doctors can now choose Amjevita instead, the first of several close copies of the popular rheumatoid arthritis drug expected this year. But industry-watchers warn consumer savings may be limited.